Ultime notizie per Novo Nordisk (NYSE:NVO) Azioni

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Biotech

Large Cap

News

Health Care

Movers

General

Novo Nordisk presenta Amicretina: una pillola che raddoppia la perdita di peso rispetto a Wegovy e potrebbe rivoluzionare il trattamento.

L&#39;Amicretina raddoppia la perdita di peso rispetto a Wegovy

Equities

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Novo Nordisk annuncia risultati positivi per il farmaco contro l&#39;obesità infantile; richiesta di approvazione a FDA ed EMA.

Novo Nordisk: il farmaco per l&#39;obesità infantile mostra buoni risultati

Market-Moving Exclusives

Exclusives

VANI

L&#39;impianto GLP-1 di Vivani Medical riduce drasticamente l&#39;82% del grasso epatico: risultati preclinici promettenti per l&#39;obesità.

L&#39;impianto di Vivani riduce drasticamente il grasso epatico

Novo Nordisk AS

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 25 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 48% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $1,872,600 and 14, calls, for a total amount of $3,590,645.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $65.0 to $145.0 for Novo Nordisk during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $65.0 to $145.0 over the preceding 30 days.
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732308891_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$7.8</td>
<td>$7.6</td>
<td>$7.8</td>
<td>$102.00</td>
<td>$1.3M</td>
<td>270</td>
<td>1.7K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.2</td>
<td>$4.9</td>
<td>$5.2</td>
<td>$100.00</td>
<td>$780.0K</td>
<td>4.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.85</td>
<td>$3.65</td>
<td>$3.84</td>
<td>$115.00</td>
<td>$686.9K</td>
<td>2.9K</td>
<td>1.9K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$13.45</td>
<td>$13.1</td>
<td>$13.15</td>
<td>$105.00</td>
<td>$636.4K</td>
<td>1.1K</td>
<td>984</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.25</td>
<td>$5.15</td>
<td>$5.15</td>
<td>$100.00</td>
<td>$257.5K</td>
<td>4.6K</td>
<td>500</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>With a volume of 4,857,497, the price of NVO is up 2.5% at $105.2. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 68 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $160.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In NVO Options

CTLT

EU Antitrust Regulators Expected to Approve Novo Holdings' $16.5B Acquisition of Catalent Without Conditions

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over <a href="https://www.benzinga.com/quote/LLY/news">the last month</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" alt="" class="wp-image-658564" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.
Could the selloff be an overreaction?
Read Also: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a>
<h2 class="wp-block-heading">Bearish Signals Galore For LLY Stock</h2>
Lilly stock is trading beneath its eight-, 20-, and 50-day exponential moving averages, firmly positioning it in a bearish trend. The Relative Strength Index (RSI) of 33.02 indicates the stock is teetering on oversold territory, while the MACD at negative 37.55 confirms strong downward momentum.
Even the 200-day simple moving average of $835.76 is now a distant memory, amplifying concerns.
<h2 class="wp-block-heading">Kennedy Sends Drugmakers Tumbling</h2>
The broader selloff in anti-obesity drugmakers like Eli Lilly, Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) has been linked to fears over the possible appointment by President-elect Donald Trump of Robert F. Kennedy Jr. as head of the Department of Health and Human Services.
Investors worry his critical stance on GLP-1 weight-loss treatments could lead to reduced insurance coverage or pricing pressures. While the agency has limited power to enact sweeping changes without Congress, the uncertainty has spooked the market.
<h2 class="wp-block-heading">Still Room To Run?</h2>
For contrarian investors, the fundamentals paint a different picture. Eli Lilly's Zepbound and Mounjaro sales are projected to hit $18 billion by 2026, doubling from 2024 estimates.
Total revenue is expected to climb to $69 billion by 2026, with earnings soaring to $30 per share — more than double the current $13.26.
And at 33.2 times forward earnings (per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), the stock's valuation looks far more attractive than its July peak of 57.2 times.
<h2 class="wp-block-heading">What's Next?</h2>
Jim Cramer's take sums up the contrarian sentiment: "This stock is as hated now as it was loved not that long ago. I think it's a buy&#8230; enough on the selling."
For long-term investors, Eli Lilly's dominance in the burgeoning obesity drug market remains a compelling growth story. 
Whether the selloff is a red flag or a golden opportunity may depend on how much faith investors have in the fundamentals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">Big Pharma&#8217;s Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a></li>
</ul>
Photo courtesy of Eli Lilly.

Long Ideas

Technicals

Politics

Trading Ideas

AMGN

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Regulations

Legal

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 45 trades.
If we consider the specifics of each trade, it is accurate to state that 57% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $549,674 and 34, calls, for a total amount of $2,045,493.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $130.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $130.0 in the last 30 days. 
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732049142_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.34</td>
<td>$2.22</td>
<td>$2.23</td>
<td>$115.00</td>
<td>$289.9K</td>
<td>11.2K</td>
<td>3.4K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.66</td>
<td>$105.00</td>
<td>$190.8K</td>
<td>2.1K</td>
<td>557</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$105.00</td>
<td>$152.7K</td>
<td>2.1K</td>
<td>994</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$19.05</td>
<td>$18.8</td>
<td>$18.8</td>
<td>$120.00</td>
<td>$112.8K</td>
<td>1.9K</td>
<td>71</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.95</td>
<td>$4.95</td>
<td>$97.50</td>
<td>$99.5K</td>
<td>2.4K</td>
<td>224</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,369,108, the price of NVO is up by 2.64%, reaching $102.44.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Novo Nordisk</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $160.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Novo Nordisk Unusual Options Activity For November 19

Danish pharmaceutical company Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) said it will officially launch its weight-loss drug Wegovy in China.
China&#8217;s National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
Wegovy is the world&#8217;s first weekly glucagon-like peptide-1 receptor agonist for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39530614/novo-nordisk-to-restrict-initial-wegovy-sales-in-china-amid-high-demand" rel="noreferrer noopener">long-term weight management</a>.
China&#8217;s National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one weight-related complication.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41775675/ozempicwegovy-maker-maintains-q3-sales-growth-on-booming-demand" rel="noreferrer noopener">Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand</a>
Initial sales of Wegovy in China will begin at a public hospital in Shanghai, where the first prescriptions are set to be issued this week, the&nbsp;financial media company&nbsp;Yicai&nbsp;<a target="_blank" href="https://www.yicaiglobal.com/news/novo-nordisks-weight-loss-drug-to-start-sales-in-china" rel="noreferrer noopener">noted</a>.
The cost of a four-injection pack is reported to be around $194 (CNY 1,400) compared to around $1,349 per patient <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39042551/novo-nordisk-faces-scrutiny-over-high-prices-of-ozempic-and-wegovy-blames-us-health-system" rel="noreferrer noopener">per month in the U.S</a>.
A month&#8217;s prescription for Wegovy costs $186 in Denmark, $140 in Germany, and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41010577/novo-nordisk-to-consider-ways-for-patients-to-affordably-access-weight-loss-drugs-ozempic-wegovy-" rel="noreferrer noopener">$92 in the U.K</a>.
In the U.S., Novo Nordisk has been criticized for charging high prices for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Wegovy and Ozempic</a>.
While Novo Nordisk&#8217;s CEO&nbsp;Lars Fruergaard Jørgensen&nbsp;has defended the high U.S. prices of the company&#8217;s blockbuster drugs,&nbsp;Ozempic&nbsp;and&nbsp;Wegovy, stating that these medications are reducing the economic burden of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-" rel="noreferrer noopener">obesity-related health issues</a>.
Due to the tight supply, access to the medication will be somewhat limited initially, requiring patients to schedule outpatient appointments and undergo a medication assessment.
Currently, Wegovy is not included in China&#8217;s national medical insurance program.
Zhou Xiaping, Novo Nordisk&#8217;s global senior vice president and president for China, noted that the company is actively pursuing strategies to make the drug more affordable, including potential partnerships with commercial insurance providers.
The Bloomberg report <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-18/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-us" rel="noreferrer noopener">adds</a> that while many patients in the U.S. and Europe get some help with drug costs through insurance, most Chinese consumers will need to pay for the drug themselves.
Price Action: NVO stock is down 1.67% at $100.04 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Emerging Markets

Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost

<a href="https://www.bloomberg.com/news/articles/2024-11-18/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-us">https://www.bloomberg.com/news/articles/2024-11-18/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-us</a>
&nbsp;
Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.&nbsp;

Global

'Novo Nordisk Launches Wegovy in China With Prices Well Below US' - Bloomberg News

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-15_08h38_46.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Powell Speaks The Truth</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-powell-speech-trump-appointments-spy-mc-11152024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>It is worth a reminder that The Arora Report is politically agnostic.&nbsp; Our sole job is to help our members extract the maximum amount of money out of the markets with the least possible risk.</li>
<li>The price action on the chart shows that the rip roaring Trump rally is taking a breather.</li>
<li>The chart shows that the stock market is still above the breakout line.</li>
<li>RSI on the chart shows that the stock market has pulled back, reflecting a loss of momentum. The stock market is still overbought.</li>
<li>The chart shows that the volume remains low.&nbsp; This indicates that institutional investors are not rushing to buy stocks.</li>
<li>Yesterday, Powell spoke that truth – the market did not like it.&nbsp; Powell said, "The economy is not sending any signals that we need to be in a hurry to lower rates."&nbsp; Powell elaborated, "The strength we are currently seeing in the economy gives us the ability to approach our decisions carefully."</li>
<li>Powell's remarks brought some selling into stocks and bonds.</li>
<li>This morning, in the early trade, selling continues.</li>
<li>The reason for some selling is that the prevailing wisdom on Wall Street has been that another rate cut in December was a sure thing.&nbsp; The Arora Report has been questioning Wall Street's wisdom and sharing with you that the data does not support another rate cut.</li>
<li>Some conservative commentators are upset believing that the reason Powell started rate cuts with a 50 bps cut was to help Kamala Harris get elected.&nbsp; Now that Trump has been elected, Powell is in no hurry to cut rates.</li>
<li>In The Arora Report analysis, even though the data does not support a rate cut in December, Powell is going to feel pressure from Trump and Republicans to cut rates.&nbsp; There is also a significant amount of data between now and the December Fed meeting.</li>
<li>In The Arora Report analysis, based on a 360 degree view, including the political pressure and the pressure from Wall Street to cut rates, the probability of a rate cut in December is now about 60%.&nbsp;&nbsp;</li>
<li>There is consternation about several Trump picks.&nbsp; Impacting the market most are Trump's picks of RKF Jr, Matt Gaetz, and Pete Hegseth.&nbsp; These picks are bringing selling in vaccine makers such as Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).&nbsp; There is also selling in other healthcare stocks, including weight loss drug companies Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and packaged food stocks such as The Kraft Heinz Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>).&nbsp; There is also selling in defense stocks such as Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), and Rtx Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>).&nbsp; There is also selling in big tech stocks.</li>
<li>The latest economic data is strong.&nbsp; The U.S. economy is about 70% consumer based.&nbsp; For this reason, prudent investors pay attention to retail sales.&nbsp; Here are the details of the just released data:
<ul>
<li>Retail sales came at 0.4% vs. 0.3% consensus.</li>
<li>Retail sales ex-auto came at 0.1% vs. 0.2% consensus.</li>
</ul>
</li>
<li>There are hundreds of indicators.&nbsp; At The Arora Report, the system has been refined through decades of research to share with you only those indicators that matter.&nbsp; Normally, we do not mention the NY Fed Empire State Manufacturing Index.&nbsp; Today, we are mentioning it due to its exceptional strength.&nbsp; The index came at 31.2 vs. 3.3 consensus.&nbsp; This indicates that manufacturing in the New York area has picked up steam. &nbsp; If similar strength is happening in the rest of the country, that would argue against further cutting interest rates. The problem for investors is that stock valuations are so high that to sustain them, rate cuts are needed.&nbsp;&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
In the early trade, money flows are negative in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Even the slightest dips in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) are being bought.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Federal Reserve

$BTC

AAPL

AMZN

BNTX

GOOG

MRNA

MSFT

NVAX

NVDA

TSLA

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth

WIIM

VRTX

Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $412,586, and 2 are calls, for a total amount of $75,090.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $82.5 to $120.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $82.5 to $120.0 over the preceding 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731685576_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$161.8K</td>
<td>653</td>
<td>693</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.66</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$90.00</td>
<td>$81.0K</td>
<td>9.9K</td>
<td>1.1K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$5.05</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$105.00</td>
<td>$45.5K</td>
<td>740</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$19.15</td>
<td>$19.05</td>
<td>$19.05</td>
<td>$120.00</td>
<td>$43.8K</td>
<td>3.3K</td>
<td>42</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$92.50</td>
<td>$39.0K</td>
<td>653</td>
<td>162</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,812,025, with NVO's price down by -3.84%, positioned at $101.28.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 75 days.</li>
</ul>
<h3>What Analysts Are Saying About Novo Nordisk</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $158.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $160. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

This Is What Whales Are Betting On Novo Nordisk

On Tuesday, a Cantor analyst wrote that additional data from Amgen&#8217;s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
On Wednesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, &#8220;Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41932478/amgen-provides-statement-on-maritide-phase-1-data" rel="noreferrer noopener">later this year</a>.&#8221;
CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html" rel="noreferrer noopener">highlighted</a> that MariTide could be a strong new contender in the weight loss drug market. Unlike current weekly injections from Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), MariTide is taken once a month and works through a different mechanism.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41928127/jim-cramer-says-eli-lillys-pathetic-stock-performance-could-get-a-breather-if-amgen-has-hidden-bone-risk-data-after-7-stock-drop" rel="noreferrer noopener">Jim Cramer Says Eli Lilly&#8217;s &#8216;Pathetic&#8217; Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop</a>
Analysts referred to new public data from a phase one study, showing that the highest dose of MariTide (420 milligrams) was associated with around 4% decrease in bone mineral density over 12 weeks.
Goldman Sachs responded that after reviewing the data, they do not believe it shows any safety issues.
Goldman Sachs says BMD measurements from DEXA scans and believes concerns about the data are not justified as there is no significant difference between the treatment and placebo, nor any clear dose-dependent effect in the DEXA data.
The analyst also says a study by Amgen&#8217;s deCODE genetics, which included data from 1.2 million people, found no link between obesity-related variants in the GIPR gene and a higher risk of fractures or lower BMD. It&#8217;s already well-established that rapid weight loss is linked to BMD loss.
William Blair notes that at lower doses of AMG 133 (140 mg and 280 mg), the reduction in bone mineral density is minimal, around 2% at most, which might not differ significantly from the placebo due to limited data in smaller groups.
While the 4% reduction stands out compared to typical reductions of 2% to 2.5%, bariatric surgery has been known to reduce BMD by 3% to 5% after six months.
MariTide, which leads to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">more significant weight loss</a> over six months than semaglutide or liraglutide, may also result in greater BMD reductions due to this weight change.
Price Action: AMGN stock is up 1.39% at $302.98 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a></li>
</ul>

Analyst Color

Analyst Ratings

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

Health and wellness platform Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), which has gained traction for its obesity-related portfolio, has highlighted the ongoing difficulties Americans face in accessing <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41811226/compounded-versions-of-weight-loss-and-diabetes-drugs-led-to-death-and-hospitalization-novo-nordi" rel="noreferrer noopener">branded GLP-1 medications</a>.
To address the issue, the company launched a GLP-1 Supply Tracker, allowing individuals to report their experiences and advocate for improved access to essential medication.
The move comes despite last week's update when the FDA revised its shortage list to&nbsp;note&nbsp;that the .25 mg starter dose of semaglutide-based obesity med Wegovy is now&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial" rel="noreferrer noopener">available in the U.S</a>.
Last month, the FDA removed&nbsp;Eli Lilly And Co's&nbsp;(NYSE: LLY) tirzepatide <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41232660/fda-sparks-controversy-with-sudden-removal-of-eli-lillys-weight-loss-drug-from-shortage-list" rel="noreferrer noopener">from its shortage list</a>.
Since September, Hims &amp; Hers has been collecting data on these access issues. Nearly 80,000 individuals on their platform reported difficulties in obtaining branded GLP-1s, with notable challenges in states with high obesity rates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41190700/hims-hers-health-asserts-demand-for-its-compounded-weight-loss-offering-to-continue" rel="noreferrer noopener">Hims &amp; Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages</a>
In Texas, for example, nearly 5,000 customers shared their struggles in acquiring the needed treatment.
The company has been in dialogue with state and federal agencies, relaying its users' experiences to advocate for policy improvements.
The newly launched GLP-1 Supply Tracker aims to deepen understanding of nationwide access challenges.
Within its first week, nearly 7,000 individuals reported difficulties, particularly with medications containing semaglutide, which emerged as the most challenging to obtain.
Semaglutide is an active ingredient in Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy.
The tool serves as a data collection and advocacy resource, providing the FDA with insights into supporting better healthcare access.
The shortage of branded GLP-1 medications reflects a broader issue in the healthcare landscape, with supply often falling short of surging demand.
Although no formal reports have comprehensively assessed the impact, Hims &amp; Hers' research revealed that nearly 30% of their weight loss customers prescribed branded GLP-1s could not fill their prescriptions due to pharmacy shortages. This trend aligns with a surge in demand as awareness of these treatments grows.
The University of Southern California reported a 442% increase in semaglutide prescriptions from January 2021 to December 2023.
In September, Hims &amp; Hers Health launched the Service Appreciation Initiative, offering compounded GLP-1 weight loss medications to some personnel for as&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/09/40944130/hims-hers-to-offer-access-to-compounded-diabetes-and-weight-loss-drugs-for-just-99month-to-certain-p" rel="noreferrer noopener">low as $99 per month</a>.
The initiative covers eligible U.S. military personnel, veterans, teachers, nurses, and first responders.
Price Action: HIMS stock is up 5.77% at $28.23 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41946311/boeing-forecasts-67-growth-in-global-air-cargo-fleet-by-2043-driven-by-asia-demand" target="_blank" rel="noreferrer noopener">Boeing Forecasts 67% Growth In Global Air Cargo Fleet By 2043, Driven By Asia Demand</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

What's Going On With Hims & Hers Health Stock On Wednesday?

Ahead of World Diabetes Day, Doctors Without Borders/Médecins Sans Frontières (MSF) called for all insulin manufacturers to provide injection pen devices at $1 per pen.
The humanitarian organization <a target="_blank" href="https://www.doctorswithoutborders.org/latest/eli-lilly-novo-nordisk-and-sanofi-must-make-insulin-pens-available-1-each" rel="noreferrer noopener">emphasized</a> that this would help ensure access to life-saving treatment for millions in low- and middle-income countries, where many struggle to afford diabetes care.
MSF highlighted that Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), which dominate the global insulin market, have the power to set high <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40731728/eli-lillys-once-weekly-insulin-shows-non-inferior-blood-sugar-reduction-vs-frequently-used-daily-" rel="noreferrer noopener">prices that restrict access</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a>
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
For instance, a pen costs $1.99 in South Africa, $5.77 in India, $14.00 in the Philippines, and $90.69 in the U.S.
Dr. Helen Bygrave, an advisor for MSF's Access Campaign, underscored the disparity by recalling the initial intentions of the scientists who discovered insulin. "Over 100 years ago, they sold the patent for just $1 to ensure global access. Now, only about half of those who need insulin can access it," she said.
She stated that the corporate control by Eli Lilly, Novo Nordisk, and Sanofi has led to a "double standard" that hinders equitable diabetes treatment.
In July, the FDA rejected Novo Nordisk's BLA filing for the once-<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty" rel="noreferrer noopener">weekly insulin icodec</a>.
Insulin pens, known for their dosing accuracy and user-friendly design, have been preferred by 82% of surveyed diabetes patients due to their convenience and less invasive administration compared to vials and syringes.
Recently, Novo Nordisk decided to cease insulin pen production to prioritize its GLP-1 medications for diabetes and obesity, like <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41775675/ozempicwegovy-maker-maintains-q3-sales-growth-on-booming-demand" rel="noreferrer noopener">Ozempic and Wegovy</a>.
This shift, motivated by profit margins in wealthier markets, could force many patients back to using syringes and vials.
South Africa, which transitioned to insulin pens in its public sector in 2014, recently faced a shortage that led to rationing when Novo Nordisk paused the supply of human insulin pens to the government.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41936736/fda-commissioner-califf-candid-on-trumps-impact-we-just-dont-know-whats-going-to-happen" target="_blank" rel="noreferrer noopener">FDA Commissioner Califf Candid on Trump's Impact: ‘We Just Don't Know What's Going to Happen'</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price

Amgen Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC&#8217;s Jim Cramer suggested the news could benefit rival Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
What Happened: Previously undisclosed data from MariTide&#8217;s Phase 1 trial showed a 4% decrease in bone mineral density among participants receiving a 420mg dose during the 12-week multiple ascending dose study. According to Olivia Brayer of Cantor Fitzgerald, the information emerged from hidden tabs in extended data files related to the trial.
MariTide, positioned as a monthly alternative to weekly injections offered by competitors Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly, operates through a different weight loss mechanism. The drug&#8217;s development has attracted significant attention due to its potential to disrupt the growing obesity treatment market.
&#8220;If Amgen has hidden bone risk data for its obesity drug, that&#8217;s huge news for Lilly which has become a pathetic stock of late,&#8221; Cramer wrote on X, formerly Twitter, announcing plans to discuss the implications at an upcoming meeting.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If Amgen has hidden bone risk data for its obesity drug , that&#39;s huge news for Lilly which has become a pathetic stock of late. Club name.. will talk about it at Thursday&#39;s meeting
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1856424358564245623?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/24/11/41927291/mara-holdings-soundhound-ai-spotify-rivian-tesla-why-these-5-stocks-are-on-investors-radars-today">MARA Holdings, SoundHound AI, Spotify, Rivian, Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Why It Matters: Despite concerns, Cantor Fitzgerald maintained its Overweight rating on Amgen with a $405 price target. The firm acknowledged that while some bone density loss is expected during weight loss treatments, particularly with a suboptimal diet, the dose-dependent increase in bone density loss could raise red flags.
The analysis also revealed data about AMG 598, a predecessor molecule that Amgen may have been investigating to challenge assumptions about GIPR antagonism&#8217;s role in bone density loss.
Price Action: Eli Lilly stock closed at $818.86 on Tuesday, down 1.63% for the day, with a slight drop of 0.10% in after-hours trading. Despite this, the stock has seen a strong 38.27% increase year-to-date. 
Meanwhile, Amgen ended the day at $298.84, down 7.14%. However, it saw a slight recovery after hours, rising 0.61%. Amgen's stock has gained 0.49% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41927913/amazon-confirms-vendor-data-breach-affecting-2-8m-employee-contacts-adds-to-growing-list-of-moveit-hack-victims">Amazon Confirms Vendor Data Breach Affecting 2.8M+ Employee Contacts, Adds To Growing List Of MOVEit Hack Victims</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$42.6K</td>
<td>3.5K</td>
<td align="right">672</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$62.50</td>
<td>$50.2K</td>
<td>2</td>
<td align="right">446</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$30.00</td>
<td>$28.1K</td>
<td>7.0K</td>
<td align="right">252</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$51.9K</td>
<td>1.1K</td>
<td align="right">72</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$35.00</td>
<td>$34.0K</td>
<td>38</td>
<td align="right">71</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$36.6K</td>
<td>595</td>
<td align="right">61</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$27.0K</td>
<td>49</td>
<td align="right">59</td>
</tr>
<tr>
<td>IONS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.00</td>
<td>$25.0K</td>
<td>331</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$41.7K</td>
<td>1.1K</td>
<td align="right">42</td>
</tr>
<tr>
<td>RGEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$130.00</td>
<td>$33.0K</td>
<td>21</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 430 day(s) on January 16, 2026. Parties traded 49 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $42.6K, with a price of $870.0 per contract. There were 3515 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with bearish sentiment. It expires in 185 day(s) on May 16, 2025. Parties traded 54 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 2 open contracts at this strike prior to today, and today 446 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 402 day(s) on December 19, 2025. Parties traded 225 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $125.0 per contract. There were 7032 open contracts at this strike prior to today, and today 252 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with bullish sentiment. It expires in 66 day(s) on January 17, 2025. Parties traded 30 contract(s) at a $315.00 strike. The total cost received by the writing party (or parties) was $51.9K, with a price of $1730.0 per contract. There were 1132 open contracts at this strike prior to today, and today 72 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be bullish, expiring in 276 day(s) on August 15, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 38 open contracts at this strike prior to today, and today 71 contract(s) were bought and sold. 
• For JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we notice a put option sweep that happens to be bullish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 61 contract(s) at a $50.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $601.0 per contract. There were 595 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 36 contract(s) at a $340.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $750.0 per contract. There were 49 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For IONS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), we notice a call option trade that happens to be bullish, expiring in 794 day(s) on January 15, 2027. This event was a transfer of 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 331 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be neutral, expiring in 66 day(s) on January 17, 2025. This event was a transfer of 39 contract(s) at a $100.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.7K, with a price of $1070.0 per contract. There were 1154 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding RGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on November 15, 2024. Parties traded 20 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $1650.0 per contract. There were 21 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCS

IONS

JANX

RGEN

TGTX

10 Health Care Stocks Whale Activity In Today's Session

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 23 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 26% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $401,684, and 14 were calls, valued at $675,514.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $200.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $70.0 to $200.0 over the preceding 30 days.
<h3>Novo Nordisk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731357036_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.28</td>
<td>$2.19</td>
<td>$2.25</td>
<td>$125.00</td>
<td>$112.3K</td>
<td>6.6K</td>
<td align="right">702</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$10.7</td>
<td>$10.65</td>
<td>$10.65</td>
<td>$115.00</td>
<td>$93.7K</td>
<td>1.1K</td>
<td align="right">100</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.65</td>
<td>$13.5</td>
<td>$13.6</td>
<td>$100.00</td>
<td>$85.6K</td>
<td>1.1K</td>
<td align="right">78</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$36.25</td>
<td>$35.95</td>
<td>$35.95</td>
<td>$145.00</td>
<td>$71.9K</td>
<td>11</td>
<td align="right">20</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.37</td>
<td>$2.26</td>
<td>$2.37</td>
<td>$120.00</td>
<td>$70.6K</td>
<td>9.7K</td>
<td align="right">632</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Novo Nordisk</h3>
<ul>
<li>With a trading volume of 3,829,487, the price of NVO is up by 1.72%, reaching $109.05.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 79 days from now.</li>
</ul>
<h3>What The Experts Say On Novo Nordisk</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $158.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $156. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Novo Nordisk with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Decoding Novo Nordisk's Options Activity: What's the Big Picture?

Germany-based Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is trading on Monday after a report that suggests the company is a takeover target.
The private equity firm Triton Partners&nbsp;is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter.
In an SEC filing, Evotec <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1412558/000119312524254399/d872020dsc13d.htm" rel="noreferrer noopener">reported</a> that Triton had acquired a 9.99% stake in the company via several open-market transactions.
The company <a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048867/novo-nordisk-and-evotec-collaborate-on-stem-cell-based-therapy-development" rel="noreferrer noopener">Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development</a>
According to the report, the investment firm has been trying to meet with senior Evotec executives as it looks into a possible buyout.
If Triton wants to increase its stake to 10% or more, it would need approval for foreign investment, the <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-11/triton-is-said-to-weigh-takeover-deal-for-drug-developer-evotec" rel="noreferrer noopener">report</a> added.
Any major move would also require backing from Evotec&#8217;s key shareholders, including Novo Holdings, the parent company of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and the Abu Dhabi-based Mubadala Investment.
Last week, the German company reported third-quarter revenues of 184.89 million euros, down from 196.28 million a year ago, <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG-DE/2024-11-06_9M_Analyst-call-presentation.pdf" rel="noreferrer noopener">noting</a> a soft market in shared R&amp;D.
It <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG/Financial_Publications/Interim-Statement-9M-2024-English.pdf" rel="noreferrer noopener">reported</a> an operating loss of 26.46 million euros, compared to 12.19 million euros loss a year ago.
In its second-quarter earnings, Evotec&#8217;s CEO said the company is operating in a more challenging market environment, notably the slowdown of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">early-stage R&amp;D spending</a>.
In October, Evotec announced advancements in its strategic partnership with&nbsp;Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which is&nbsp;focused on developing a molecular <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41490865/why-is-evotec-stock-gaining-today" rel="noreferrer noopener">glue-based pipeline</a>.
Price Action: EVO stock is up 16.2% at $4.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41877517/ge-healthcare-and-deephealth-team-up-to-advance-ai-powered-breast-cancer-screening" target="_blank" rel="noreferrer noopener">GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details</a></li>
</ul>

Rumors

Media

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. 
According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. 
This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.
Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. 
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. 
Similarly, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.
Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. 
Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.
On the downside, Wegovy maker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.
Similarly, Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. 
Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.
&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why">ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</a></li>
</ul>
Image Via Shutterstock

ABBV

ALNY

GILD

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Earlier, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved versions of its drugs <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41527988/ozempic-can-potentially-cut-risk-of-alzheimers-compared-to-other-diabetic-medicines-study-shows" rel="noreferrer noopener">Wegovy and Ozempic</a>.
Amid shortages and rising demand for branded drugs, compounded semaglutide has gained popularity due to its affordability.
However, Novo Nordisk contends that only FDA-approved versions should be available, emphasizing the safety risks associated with compounded drugs.
Novo Nordisk&#8217;s Chief Financial Officer Karsten Munk Knudsen has reportedly confirmed that the company was aware of at least ten deaths and 100 hospitalizations linked to these compounded versions of semaglutide-based drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41436151/eli-lilly-sues-some-vendors-for-unauthorized-sale-of-fake-weight-loss-drug" rel="noreferrer noopener">Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug</a>
However, he noted that no definitive cause of death is identified in the reports, as the data is pulled from the FDA adverse events database.
Last week, the update came as the FDA revised its shortage list to&nbsp;note&nbsp;that the .25 mg starter dose of semaglutide-based obesity med Wegovy is now <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41685634/popular-weight-loss-drug-wegovy-shows-encouraging-results-in-liver-fibrosis-trial" rel="noreferrer noopener">available in the U.S</a>.
Less than a month ago, the FDA removed&nbsp;Eli Lilly And Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;tirzepatide&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41436151/eli-lilly-sues-some-vendors-for-unauthorized-sale-of-fake-weight-loss-drug" rel="noreferrer noopener">from its shortage list</a>.
Soon after the shortage was resolved, the FDA reminded compounders of the legal restrictions on making copies of FDA-approved drugs. The update has sparked concern among medical professionals, patients, and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41313216/fda-to-reassess-ban-on-cheaper-compounded-versions-of-eli-lilly-weight-loss-drugs" rel="noreferrer noopener">drug compounding facilities</a>.
A company spokesperson referred Reuters to the FDA&#8217;s database, which tracked these events over the past two years. Adverse event reports, which are submitted by doctors, patients, drugmakers, and others, are primarily used as an early warning system.
These reports are not considered conclusive evidence of causality and often lack important details. Furthermore, it is possible that multiple submissions may describe the same incident.
Knudsen also discussed the company&#8217;s ongoing efforts to address safety concerns related to compounded versions of its drugs.
He mentioned that Novo Nordisk has been monitoring the market for compounded products and has identified several safety issues.
Novo Nordisk argues that these compounded versions may pose safety risks, such as impurities and incorrect dosages, and sometimes lack the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/10/41506422/ozempic-and-wegovy-maker-novo-nordisk-asks-fda-to-halt-production-of-compounded-fat-loss-drugs-due-t" rel="noreferrer noopener">active ingredient entirely</a>.
On Wednesday, Novo Nordisk <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41775675/ozempicwegovy-maker-maintains-q3-sales-growth-on-booming-demand" rel="noreferrer noopener">released Q3 earnings</a>. &#8220;Following higher-than-expected volume growth in recent years, including GLP-1-based products such as Ozempic and Wegovy, combined with the expectation of continued volume growth and capacity limitations at some manufacturing sites, the outlook also reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies,&#8221; it added.
Price Action: NVO stock is up 1.59% at $107.04 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41806208/solaredges-tough-q3-revenue-miss-multi-billion-impairment-bleak-forecast-more" target="_blank" rel="noreferrer noopener">SolarEdge&#8217;s Tough Q3: Revenue Miss, Multi-Billion Impairment, Bleak Forecast &amp; More</a></li>
</ul>
Photo via Shutterstock

Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware

In the latest quarter, 7 analysts provided ratings for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00, and a low estimate of $156.00. A decline of 0.36% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1730923248_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Novo Nordisk by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$156.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Novo Nordisk. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Novo Nordisk compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Novo Nordisk's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Novo Nordisk's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NVO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Novo Nordisk analyst ratings.</a>
<h2>All You Need to Know About Novo Nordisk</h2>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Novo Nordisk's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Novo Nordisk showcased positive performance, achieving a revenue growth rate of 25.34% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Novo Nordisk's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.46%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Novo Nordisk's ROE stands out, surpassing industry averages. With an impressive ROE of 18.97%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Novo Nordisk's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.0% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Novo Nordisk's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.51.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Novo Nordisk

Optimism over global healthcare sector rises: Jefferies

Franklin International Equity Fund Q3 2024 Commentary

Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug's pens

Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735

Catalent gains on report it's likely to be granted EU approval for Novo Holdings deal

Catalent gains on reports it's likely to be granted EU approval for Novo Holdings deal (update)

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed $16.5B...

Novo slated to win EU approval for Catalent takeover, Reuters says

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

The launch of Madrigal Pharmaceuticals Inc.'s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

MDGL: A Promising Play In The Weight Loss Drug Space

Stocks of anti-obesity drugmakers Eli Lilly (LLY), Novo Nordisk (NVO), and Amgen (AMGN) have gotten hit as the market frets over what a Robert F. K...

Eli Lilly, others to buy after RFK-inspired drop, Barron's says

ALHC

ALIZF

ALIZY

ASML

ASMLF

BIIB

CLOV

DTEGF

DTEGY

HTHIF

HTHIY

KNAMF

MDGL

MZDAF

MZDAY

NONOF

NSRGF

NSRGY

NVSEF

RHHBF

RHHVF

RYDAF

SAPGF

SHEL

SNYNF

UNCFF

UNCRY

VKTX

YPHDF

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Press Releases

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Management

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Opinion

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

BioRestorative Ends Q3 In 'Strong' Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Comments

Novo Nordisk

Notizie

Ultime notizie per Novo Nordisk (NYSE:NVO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO